Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Davinci Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,206,829

411 payments

Through program year 2025, Davinci Research LLC is reported as receiving $1,206,829 in research payments, across 411 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $592,187 50
2024 Research $140,537 130
2023 Research $220,977 110
2022 Research $180,146 98
2021 Research $46,152 8
2020 Research $26,830 15

Breakdown

Who paid Research payments · program years 2020–2025
  1. Sanofi US Services Inc. $423,029 29 payments
  2. GlaxoSmithKline, LLC. $344,797 60 payments
  3. Biohaven Pharmaceutical Holding Company Ltd. $296,868 290 payments
  4. Stryker Corporation $52,007 21 payments
  5. Eli Lilly and Company $45,731 2 payments
  6. Insmed, Inc. $25,634 2 payments
  7. Regeneron Pharmaceuticals, Inc. $13,365 3 payments
  8. Paratek Pharmaceuticals, Inc. $5,398 4 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized, Double-blind, Placebo-controlled, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab in Participants With Inadequately Controlled Chronic Rhinosinusitis Without Nasal Polyps $284,388 14 payments
  2. A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Para $186,399 34 payments
  3. A Phase 23 Doubleblind Randomized Placebocontrolled Safety and Efficacy Trial of Bhv3000 Rimegepant Orally Disintegrating Tablet Odt for the Acute Treatment of Chronic Rhinosinusitis CRS With Or Without Nasal Polyps $160,875 199 payments
  4. A Phase 2/3 Double-Blind Randomized Placebo-Controlled Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Chronic Rhinosinusitis (CRS)With or Without Nasal Polyps $135,993 91 payments
  5. A Randomised, Double-Blind, Parallel Group Phase III Study to Assess T $87,915 19 payments
  6. A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) $81,597 9 payments
  7. A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $70,483 7 payments
  8. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ Ly3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on A Background Therapy With Intranasal Corticosteroids $45,731 2 payments
  9. A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) $44,319 4 payments
  10. Insmed BIRCH Study $25,634 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record